Enjoy complimentary customisation on priority with our Enterprise License!
The global sinusitis drugs market size is estimated to grow by USD 735.7 million at a CAGR of 5.53% between 2023 and 2028. The market growth of sinusitis treatment hinges on several key factors. Firstly, the rising prevalence of sinusitis, fueled by factors like air pollution and upper respiratory tract infections, drives demand for effective therapies. Secondly, growing awareness among people about sinusitis treatment options encourages proactive healthcare-seeking behaviors, further boosting market growth. Additionally, increasing mergers and acquisitions within the pharmaceutical industry facilitate the development and distribution of innovative treatments, expanding market reach and accessibility. These factors collectively contribute to a thriving sinusitis treatment market, poised for continuous expansion in the years to come.
View the Bestselling Market Research Sample
In the market, the demand for effective therapeutic approaches drives growth, with a focus on addressing upper respiratory tract illnesses like chronic sinusitis, sub-acute sinusitis, and acute sinusitis. Diagnostic techniques such as sinus MRIs, sinus CT scans, and nasal cytology testing aid in accurate diagnosis. Challenges lie in antibiotic development amid rising antibiotic-resistant cases and in ensuring patient outcomes through precise dosage forms. Trends include the adoption of 3D navigation technology in sinusitis management and educational programs to enhance patient knowledge, mitigating errors and complications. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Mergers and Acquisitions is a key driver shaping the market. Companies in the market are increasingly engaging in mergers and acquisitions to develop novel therapies for the treatment of sinusitis. For example, Armata Pharmaceuticals completed a merger between C3J Therapeutics and AmpliPhi Biosciences to develop bacteriophage therapeutics to combat antibiotic resistance.
Furthermore, Knopp Biosciences is collaborating with UK medical research companies to evaluate the efficacy of its lead drug candidate, dexpramipexole, for treating severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Such efforts are expected to boost drug development activities and create opportunities for other companies to enter the market.
Heavy investment in R&D is a key trend. Major players in the market are investing heavily in R&D to develop new drugs for the treatment of sinusitis. LYRA THERAPEUTICS raised USD 29 million for its implant, LYR-210, which is designed using novel technologies to deliver approved steroids in the sinonasal tissues that are difficult to penetrate with traditional therapeutic options.
In addition, LYR-210 is inserted into the inflamed sinonasal area, ensuring gradual release of topical steroids for six months. Phase I trials showed it was well-tolerated and effective in reducing chronic rhinosinusitis symptoms. The emergence of novel drug delivery systems and increased investments in R&D are expected to boost the consumption of sinusitis drugs and drive market growth.
The lack of development of antibiotics to fight multidrug-resistant bacteria is a major challenge for the growth of the market. Most drugs in the pipeline are modifications of existing antibiotics, and sales of antibiotics have declined due to antibiotic resistance in sinusitis patients. Major companies such as Bayer, Merck, Novartis, Sanofi, and Pfizer have stopped investing in antibiotic research and are exiting the market.
Furthermore, Novartis sold its three antibiotics to Boston Pharmaceuticals, and Sanofi sold its antibiotic unit to Evotec. Developing new antibiotics is expensive and time-consuming, and the commercial potential and return on investment are low due to antibiotic resistance. Overuse of prescription antibiotics is the main cause of rising resistance, hindering the development of novel antibiotics. This lack of investment in antibiotics may cause a decline in the growth of the market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbvie Inc - The company offers sinusitis drugs such as RINVOQ (upadacitinib). Also, they conduct research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance globally to achieve its established long-term strategic goals.
The market growth and forecasting report also includes detailed analyses of the competitive landscape of the market and information about prominent and key market companies, including:
Technavioâs market research and growth report consists of a holistic analysis of the key development analysis, development stage, key market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
In the market, segmentation is essential to address the diverse needs and conditions associated with upper respiratory tract illnesses. From pediatric to adult populations, effective diagnostic techniques such as sinus MRIs, CT scans, and nasal cytology testing aid in accurately diagnosing various forms of sinusitis, including chronic, sub-acute, and acute sinusitis. As pollution levels and upper respiratory tract infection cases rise, there is a growing demand for therapeutic approaches that utilize innovative solutions like 3D navigation technology to improve patient outcomes and minimize errors and complications. Antibiotic development and the introduction of new dosage forms cater to evolving patient needs, while educational programs enhance patient knowledge about sinusitis management and preventive measures. With a focus on addressing conditions like meningitis and brain abscess stemming from sinusitis complications, the market continues to evolve to meet the diverse needs of patients and healthcare providers alike.
The market share growth by the steroid nasal sprays segment will be significant during the forecast period. The high market share of this segment is attributed to the therapeutic efficacy of these drugs in relieving the signs and symptoms of sinusitis. Steroid nasal sprays are used as off-label prescription drugs. They act by reducing swelling and mucus production, thus relieving the symptoms of nasal congestion and improving the drainage of fluid from the sinus. However, these drugs do not provide immediate relief of symptoms and may require multiple administrations to yield the desired outcome. These drugs are often used in combination with nasal wash for better outcomes in patients with sinusitis and other nasal problems. Flonase, NASACORT AQ, Nasonex, Rhinocort, Zetonna, and QNASL are some of the steroid nasal sprays available in the market. Such factors are driving market growth.
Get a detailed analysis of various segments View Sample PDF
For more insights on the market share of various regions View PDF Sample now!
North America is projected to contribute 39% of market growth by 2028. Technavioâs analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market growth in this region is attributed to the increased investments in R&D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region. Also, Genentech is also engaged in conducting Phase II clinical trials on XOLAIR (omalizumab) for the treatment of nasal polyps. The successful launch of new drugs for these indications will result in a paradigm shift from small molecules to biologics and also pave the path for other companies to enter the market, which contributes to market growth.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
In the dynamic landscape of the market, addressing the needs of both children and adults is paramount, with a focus on innovative therapeutic approaches and fresh respiratory remedies. Drug companies invest significant R&D expenditures to develop medications targeting sinus congestion and inflammation, leveraging advancements in diagnostics like ciliary function tests and blood tests to tailor treatment types, including nasal corticosteroids and nasal surgery. With rising concerns over air pollution and its impact on the nasal mucosa, medication makers strive to combat pollutants and enhance the immune system response. The market introduction of novel treatments like Optinose XHANCE addresses unmet needs in sinus pain relief and inflammation treatment, aligning with initiatives by organizations like the World Allergy Organization to improve patient outcomes and quality of life.
|
Industry Scope |
|
|
Report Coverage |
Details |
|
Page number |
178 |
|
Base year |
2023 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.53% |
|
Market growth 2024-2028 |
USD 735.7 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.13 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Bayer AG, Bionpharma Inc., CHIESI Farmaceutici SpA, Cipla Inc., Dr Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Neopharma Corp., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teligent Inc., and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
|
Customization purview |
If our market forecasting report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.